NeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy, Liver Fibrosis Success
NeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy, Liver Fibrosis Success
NeuroBo Pharmaceuticals Inc (NASDAQ:NRBO) shares were down more than 6% at last check Wednesday.
在週三的最後一次檢查中，NeuroBo製藥公司（納斯達克股票代碼：NRBO）股價下跌了6％以上。
The Boston-based company announced preclinical data for its novel "G-Protein-Coupled Receptor 119 (GPR119) agonist," known as DA-1241.
這家總部位於波士頓的公司公佈了其名爲 DA-1241 的新型 “G蛋白偶聯受體119（GPR119）激動劑” 的臨床前數據。
The data from a study on mice suggests that DA-1241 — combined with Novo Nordisk A/S's (NYSE:NVO) semaglutide (Wegovy) — improves liver fibrosis. It also demonstrates additive hepatoprotective effects compared to either treatment alone.
一項小鼠研究的數據表明，DA-1241 ——與諾和諾德A/S（紐約證券交易所代碼：NVO）的索瑪魯肽（Wegovy）聯合使用——可以改善肝纖維化。與單獨使用任何一種治療相比，它還顯示出額外的保肝作用。
DA-1241 did not influence liver weight, the company said.
該公司表示，DA-1241 沒有影響肝臟重量。
In contrast, semaglutide reduced body weight by approximately 25% and improved hepatomegaly in GAN DIO-MASH mice with or without combination treatment.
相比之下，無論是否進行聯合治療，索瑪魯肽使體重降低了約25％，並改善了GAN DIO-MASH小鼠的肝腫大。
There was no additional weight loss in the combination group compared to semaglutide alone.
與單獨使用索瑪魯肽相比，組合組沒有額外的體重減輕。
- DA-1241 and semaglutide monotherapy each improved NAS (≥2-point) in 21% of mice
- Combination treatment led to marked improvements (≥2-point in 80% of mice and ≥1-point in all mice), driven by reduction in steatosis and lobular inflammation scores.
- Combination therapy synergistically promoted quantitative histology for steatosis compared to monotherapies.
- Treatments did not significantly influence quantitative markers of fibrosis (PSR, Col1a1)
- DA-1241 and semaglutide in monotherapy lowered α-SMA levels with further improvement in combination treatment, suggesting additive inhibitory effects on fibrogenesis.
- At the end of treatment, semaglutide reduced body weight by approximately 17% (p < 0.05 vs. vehicle control), while DA-1241 (-2.8%) showed little effect.
- There was no additional weight loss in the combination group (-19%, p < 0.05) compared to semaglutide alone.
- Collagen fiber deposition was prominent in mice treated with vehicle compared to the normal control group.
- DA-1241 和索瑪魯肽單一療法分別改善了 21% 小鼠的 NAS（≥2 點）
- 在脂肪變性和小葉炎評分下降的推動下，聯合治療帶來了顯著改善（80% 的小鼠≥2分，所有小鼠≥1分）。
- 與單一療法相比，聯合療法協同促進了脂肪變的定量組織學。
- 治療沒有顯著影響纖維化的定量標誌物（PSR、Col1a1）
- 單一療法中的 DA-1241 和索瑪魯肽降低了 α-SMA 水平，聯合治療進一步改善，這表明對纖維發生有額外的抑制作用。
- 在治療結束時，索瑪魯肽使體重減輕了約17％（與車輛控制相比，p
- 與單獨使用索瑪魯肽相比，該組合組沒有額外的體重減輕（-19％，p
- 與正常對照組相比，接受載體治療的小鼠的膠原纖維沉積非常明顯。
DA-1241 or semaglutide alone lowered collagen-positive area compared to the vehicle-treated group (17.8%, 17.1% vs. 25.8%, p < 0.05). Their combination therapy elicited a further reduction to 6.05% (p < 0.05) compared with each treatment alone.
與車輛治療組相比，單獨使用 DA-1241 或索瑪魯肽可降低膠原蛋白陽性面積（17.8%，17.1% 對 25.8%，p
Price Action: NRBO shares are down 6.11% at $4.30 at last check Wednesday.
價格走勢：在週三的最後一次檢查中，NRBO股價下跌6.11％，至4.30美元。
Now Read: EXCLUSIVE – Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
立即閱讀：獨家——Roundhill Investments推出減肥ETF，用於投資Ozempic等重磅藥物
Image: Shutterstock
圖片：Shutterstock
譯文內容由第三人軟體翻譯。